Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. / Andreasen, N; Minthon, Lennart; Vanmechelen, E; Vanderstichele, H; Davidsson, P; Winblad, B; Blennow, K.

I: Neuroscience Letters, Vol. 273, Nr. 1, 1999, s. 5-8.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

APA

CBE

MLA

Vancouver

Author

Andreasen, N ; Minthon, Lennart ; Vanmechelen, E ; Vanderstichele, H ; Davidsson, P ; Winblad, B ; Blennow, K. / Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. I: Neuroscience Letters. 1999 ; Vol. 273, Nr. 1. s. 5-8.

RIS

TY - JOUR

T1 - Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment

AU - Andreasen, N

AU - Minthon, Lennart

AU - Vanmechelen, E

AU - Vanderstichele, H

AU - Davidsson, P

AU - Winblad, B

AU - Blennow, K

PY - 1999

Y1 - 1999

N2 - We studied CSF-tau and CSF-Abeta42 in 16 patients with mild cognitive impairment (MCI) who at follow-up investigations 6-27 months later had progressed to Alzheimer's disease (AD) with dementia. For comparison, we studied 15 age-matched healthy individuals. At baseline, 14/16 (88%) of MCI patients had high CSF-tau and/or low CSF-Abeta42 levels. These findings show that these CSF-markers are abnormal before the onset of clinical dementia and that they may help to identify MCI patients that will develop AD. This is especially important when drugs with potential effects on the progression of AD will reach the clinical phase.

AB - We studied CSF-tau and CSF-Abeta42 in 16 patients with mild cognitive impairment (MCI) who at follow-up investigations 6-27 months later had progressed to Alzheimer's disease (AD) with dementia. For comparison, we studied 15 age-matched healthy individuals. At baseline, 14/16 (88%) of MCI patients had high CSF-tau and/or low CSF-Abeta42 levels. These findings show that these CSF-markers are abnormal before the onset of clinical dementia and that they may help to identify MCI patients that will develop AD. This is especially important when drugs with potential effects on the progression of AD will reach the clinical phase.

U2 - 10.1016/S0304-3940(99)00617-5

DO - 10.1016/S0304-3940(99)00617-5

M3 - Article

VL - 273

SP - 5

EP - 8

JO - Neuroscience Letters

JF - Neuroscience Letters

SN - 0304-3940

IS - 1

ER -